| Not Yet Recruiting | Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS NCT04366115 | AVM Biotechnology Inc | Phase 1 |
| Not Yet Recruiting | Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD NCT07393685 | Tianjin Medical University | — |
| Active Not Recruiting | Vaccination Nudges From Pharmacists NCT07161739 | University of Calgary | N/A |
| Active Not Recruiting | A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above NCT07204964 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and NCT07121192 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | Vaccine Pandemic Preparedness Through Airway Immunology Characterization NCT05921448 | Copenhagen Respiratory Research | EARLY_Phase 1 |
| Recruiting | Clinical Trials of Quadrivalent Influenza Vaccine NCT06824519 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine NCT06800950 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Flu Infection at UPHS NCT06807840 | University of Pennsylvania | — |
| Completed | Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults NCT06602531 | Arcturus Therapeutics, Inc. | Phase 1 |
| Completed | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People NCT06683352 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complication NCT06573008 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 |
| Active Not Recruiting | Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine NCT06622590 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Trea NCT06684379 | PEACHES BIOTECH | Phase 1 / Phase 2 |
| Completed | Personalized Nudging to Increase Influenza Vaccinations NCT06566534 | Geisinger Clinic | N/A |
| Completed | A Study About Modified RNA Vaccines Against Influenza in Healthy Adults NCT06436703 | Pfizer | Phase 2 |
| Completed | A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Y NCT06431607 | GlaxoSmithKline | Phase 2 |
| Recruiting | Covid-19 and Influenza Oral Vaccine Study NCT06355232 | Vaxine Pty Ltd | Phase 1 |
| Completed | A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Agains NCT06382311 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults NCT06237049 | Pfizer | Phase 2 |
| Completed | Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine NCT06125691 | Arcturus Therapeutics, Inc. | Phase 1 |
| Completed | Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Be NCT06207929 | Evidation Health | — |
| Unknown | Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Vir NCT06315400 | Valenta Pharm JSC | Phase 4 |
| Completed | A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in NCT05648357 | GlaxoSmithKline | Phase 4 |
| Completed | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and O NCT06015282 | Seqirus | Phase 3 |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compar NCT06087640 | Seqirus | Phase 3 |
| Completed | Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults NCT06028347 | Seqirus | Phase 1 |
| Completed | A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Infl NCT05981846 | Hipra Scientific, S.L.U | Phase 2 |
| Unknown | Zoonotic Influenza Surveillance in Belgium NCT05827601 | Cyril Barbezange | — |
| Completed | Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) NCT05975840 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects NCT05955027 | Nanjing Zenshine Pharmaceuticals | Phase 1 |
| Completed | Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vacc NCT05875961 | Seqirus | Phase 1 |
| Completed | Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and NCT05874713 | Seqirus | Phase 2 |
| Suspended | Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community NCT03824847 | The University of Hong Kong | Phase 4 |
| Completed | This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-1 NCT05858450 | Pfizer | — |
| Completed | A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older A NCT05823974 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants an NCT05779020 | Butantan Institute | Phase 3 |
| Completed | Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects NCT05711797 | Nanjing Zenshine Pharmaceuticals | Phase 1 |
| Recruiting | A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza NCT05648448 | University of Oxford | Phase 2 |
| Completed | Substance Balance Study of [14C]ZX-7101A in Healthy Adult Male Subjects in China NCT05720091 | Nanjing Zenshine Pharmaceuticals | Phase 1 |
| Recruiting | An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza NCT04494412 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates A NCT05596734 | BioNTech SE | Phase 2 |
| Completed | A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus NCT06385821 | NPO Petrovax | Phase 3 |
| Terminated | Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults NCT05514002 | Fatimah Dawood | Phase 4 |
| Completed | A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older NCT05540522 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥5 NCT05501561 | Seqirus | Phase 2 |
| Completed | A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger an NCT05446740 | GlaxoSmithKline | Phase 1 |
| Completed | Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses NCT05765955 | Poolbeg Pharma plc | Phase 1 |
| Completed | A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine i NCT05422326 | Seqirus | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza NCT05702489 | Nanjing Zenshine Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute NCT05273619 | Valenta Pharm JSC | Phase 3 |
| Completed | A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of NCT05227001 | Pfizer | Phase 1 |
| Completed | Intramuscular CodaVax-H1N1 in Healthy Adults NCT05223179 | Codagenix, Inc | Phase 1 |
| Unknown | Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children NCT05739474 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years NCT05138705 | Shanghai Institute Of Biological Products | Phase 4 |
| Recruiting | Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults NCT05108818 | University of Pennsylvania | Phase 4 |
| Completed | A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Com NCT05044195 | Seqirus | Phase 3 |
| Completed | Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory V NCT05269290 | Valenta Pharm JSC | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza NCT05052697 | Pfizer | Phase 1 / Phase 2 |
| Unknown | Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks NCT05012189 | Insight Therapeutics, LLC | Phase 4 |
| Completed | Universal Anti-Viral Vaccine for Healthy Elderly Adults NCT04441047 | Mirror Biologics, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine NCT03927131 | Butantan Institute | Phase 3 |
| Unknown | Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 NCT05079152 | China National Biotec Group Company Limited | Phase 4 |
| Completed | Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute NCT05269329 | Valenta Pharm JSC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641 NCT04789577 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and NCT04790851 | China National Biotec Group Company Limited | Phase 4 |
| Completed | Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years NCT05470582 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine NCT04669691 | Seqirus | Phase 2 |
| Completed | Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vac NCT05869201 | St. Petersburg Research Institute of Vaccines and Sera | Phase 2 / Phase 3 |
| Unknown | Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures NCT04576377 | The University of Hong Kong | Phase 4 |
| Completed | Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy NCT04590066 | University of Pennsylvania | N/A |
| Completed | Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infect NCT04527614 | Sciensano | N/A |
| Completed | Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates NCT04565353 | University of Pennsylvania | N/A |
| Unknown | Evaluation of Humoral Immunity Following COVID-19 in Pregnancy NCT04568044 | Imperial College London | — |
| Completed | Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 NCT04559204 | China National Biotec Group Company Limited | Phase 4 |
| Active Not Recruiting | Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection NCT05110911 | University of Melbourne | — |
| Unknown | Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites NCT04288921 | LumiraDx UK Limited | N/A |
| Unknown | Burden of Influenza at Emergency Department (ED) Level in European Countries NCT04244500 | University of Rostock | — |
| Completed | Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine NCT05457894 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects NCT04160975 | Harvard University | N/A |
| Completed | Prevalence of Influenza RelAted Invasive Aspergillosis NCT04172610 | Karolinska University Hospital | — |
| Completed | Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vac NCT04080245 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Completed | Phase 3 Pivotal Trial of NanoFlu™ in Older Adults NCT04120194 | Novavax | Phase 3 |
| Completed | Immunologic Response to FluMist vs. Flucelvax NCT03982069 | Richard Zimmerman MD | Phase 4 |
| Completed | Financing Strategies of Influenza Vaccination in China NCT04038333 | Peking University | — |
| Unknown | Recombinant Influenza Vaccination in U.S. Nursing Homes NCT03965195 | Insight Therapeutics, LLC | Phase 4 |
| Completed | Efficacy Study With QIVc in Pediatric Subjects NCT03932682 | Seqirus | Phase 3 |
| Completed | Prophylactic Treatment With Oseltamivir NCT03899571 | University Medical Centre Ljubljana | N/A |
| Completed | Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults NCT03743688 | Vanderbilt University Medical Center | — |
| Completed | Nudging for Vaccination : Efficacity and Acceptability Among Medical Students NCT03768596 | Adriaan Barbaroux | N/A |
| Completed | Resistance Exercise to Improve Flu Vaccine for Older Adults NCT03736759 | University of Houston | N/A |
| Completed | Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the NCT03688620 | GlaxoSmithKline | Phase 4 |
| Completed | Herd Immunity and Influenza Vaccine Uptake NCT03748160 | Finnish Institute for Health and Welfare | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects NCT03657719 | Green Cross Corporation | Phase 2 |
| Terminated | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults NCT03658629 | Novavax | Phase 2 |
| Completed | Immunologic Response to Influenza Vaccination in Children and Adolescents NCT03614975 | Richard Zimmerman MD | Phase 4 |
| Completed | Adjuvanted Influenza Vaccination Year 2 Follow-On Survey NCT03599739 | Insight Therapeutics, LLC | — |
| Completed | Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2 NCT03392207 | Butantan Institute | — |
| Completed | Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenz NCT03460743 | Laboratorios Liomont | Phase 3 |
| Completed | Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department NCT02899065 | University of California, Davis | N/A |
| Completed | A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza NCT03394209 | Capital Medical University | Phase 2 |
| Completed | Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza NCT03410862 | michael macknin | Phase 4 |
| Completed | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults NCT03357263 | Green Cross Corporation | Phase 1 |
| Completed | Comparative Tests of Flu Vaccination Phone Messages NCT03332992 | University of Michigan | N/A |
| Completed | Centralized Reminder Recall - Flu RCT2 NCT03294473 | University of California, Los Angeles | N/A |
| Completed | Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults NCT03314662 | Seqirus | Phase 3 |
| Active Not Recruiting | Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong NCT03330132 | The University of Hong Kong | Phase 4 |
| Unknown | Cardiac Injury in Patients With Influenza NCT03339180 | Örebro University, Sweden | — |
| Completed | Panblok H7 Vaccine Adjuvanted With AS03 or MF59 NCT03283319 | Biomedical Advanced Research and Development Authority | Phase 2 |
| Completed | Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolesce NCT03445468 | Il-Yang Pharm. Co., Ltd. | Phase 3 |
| Completed | Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England NCT03278067 | GlaxoSmithKline | — |
| Completed | Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Coun NCT02885246 | GlaxoSmithKline | — |
| Completed | A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Invest NCT03275389 | GlaxoSmithKline | Phase 1 |
| Completed | Afluria Pregnancy Registry NCT03442582 | Seqirus | — |
| Completed | Flucelvax (TIVc or QIVc) Pregnancy Registry NCT03438487 | Seqirus | — |
| Completed | Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age NCT03165617 | Seqirus | Phase 3 |
| Completed | Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3 NCT03095599 | Institute of Vaccines and Medical Biologicals, Vietnam | Phase 2 / Phase 3 |
| Completed | Clinical Performance of the Diassess Influenza A and B Test NCT03035396 | Diassess Inc. | N/A |
| Completed | Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department NCT02957136 | University of California, Davis | N/A |
| Unknown | Assessment of the Clinical Performance of the ARROW-FLU System NCT02996136 | Sekisui Diagnostics, LLC | N/A |
| Active Not Recruiting | Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong NCT02957890 | The University of Hong Kong | Phase 4 |
| Completed | A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers NCT04372719 | SGS Life Sciences, a division of SGS Belgium NV | Phase 1 |
| Completed | Rapid Assessment of and Prophylaxis for Influenza in Dwellers of Long-term Care Facilities NCT02964871 | University of Wisconsin, Madison | N/A |
| Completed | Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra NCT02663102 | GlaxoSmithKline | — |
| Completed | A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older NCT02917304 | Green Cross Corporation | Phase 3 |
| Completed | Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis NCT02831608 | Ole Frobert, MD, PhD | Phase 4 |
| Completed | Childhood Influenza Immunisation in General Practice Invitation Trial NCT02921633 | Public Health England | N/A |
| Completed | Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months NCT03020628 | SK Chemicals Co., Ltd. | Phase 3 |
| Unknown | A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults NCT02915809 | Green Cross Corporation | Phase 3 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatr NCT02914275 | Seqirus | Phase 3 |
| Completed | Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines NCT02893878 | GlaxoSmithKline | — |
| Withdrawn | Childhood Influenza Immunisation Invitation Trial in Schools NCT02883972 | Public Health England | N/A |
| Completed | Specific Respiratory Infections as Triggers of Acute Medical Events NCT02984280 | University College, London | — |
| Completed | A Clinical Trial of KT07 Capsule in the U.S.A NCT02867358 | Yiling Pharmaceutical Inc. | Phase 2 |
| Completed | Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU NCT02998996 | Eurocine Vaccines AB | Phase 1 / Phase 2 |
| Completed | Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine NCT03028116 | Research Institute for Biological Safety Problems | Phase 1 |
| Completed | Tropical Influenza Control Strategies for the Elderly NCT02655874 | Tan Tock Seng Hospital | Phase 4 |
| Completed | Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) NCT02598089 | Institute of Vaccines and Medical Biologicals, Vietnam | Phase 1 |
| Completed | A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine NCT02585700 | Institute of Virology, Vaccines and Sera, Torlak | Phase 1 |
| Completed | Idylla IFV-RSV Panel Clinical Testing NCT02786381 | Janssen Pharmaceutica N.V., Belgium | — |
| Completed | Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old NCT02723812 | Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products | Phase 4 |
| Completed | Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly NCT02741843 | The University of Hong Kong | N/A |
| Completed | A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatr NCT02545543 | Seqirus | Phase 3 |
| Completed | The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study NCT03502291 | Liverpool University Hospitals NHS Foundation Trust | Phase 4 |
| Unknown | The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) NCT02500680 | Nova Immunotherapeutics Limited | Phase 1 |
| Completed | Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults NCT02377401 | GlaxoSmithKline | Phase 1 |
| Completed | A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents NCT02352389 | St. Jude Children's Research Hospital | — |
| Completed | Influenza Vaccine in HIV Study NCT02632578 | University of Melbourne | — |
| Completed | Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Ad NCT02480998 | Il-Yang Pharm. Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Inactivated Influenza Via Jet Injection NCT02290691 | PharmaJet, Inc. | Phase 4 |
| Completed | Promoting Influenza Vaccination In General Practice Waiting Rooms NCT03239795 | Christophe Berkhout | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years NCT02212106 | Seqirus | Phase 4 |
| Completed | Mail Outreach To Increase Vaccination Acceptance Through Engagement NCT02243774 | Brigham and Women's Hospital | N/A |
| Completed | Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents NCT02621164 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children NCT03191097 | Valenta Pharm JSC | Phase 3 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Age NCT02214225 | Seqirus | Phase 3 |
| Completed | Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers NCT02019745 | University of North Carolina, Chapel Hill | — |
| Completed | Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underly NCT02091908 | Seqirus | Phase 3 |
| Completed | Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunos NCT02107807 | Seqirus | Phase 3 |
| Withdrawn | Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Wes NCT01810731 | Centers for Disease Control and Prevention | Phase 2 / Phase 3 |
| Completed | Treatment of Severe Influenza A Infection NCT02108366 | The University of Hong Kong | Phase 3 |
| Completed | Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older NCT02101749 | Mahidol University | Phase 4 |
| Completed | Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adol NCT02621177 | SK Chemicals Co., Ltd. | Phase 3 |
| Unknown | Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults NCT01967368 | The University of Hong Kong | Phase 4 |
| Completed | MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine NCT02225327 | Korea University Guro Hospital | Phase 4 |
| Completed | Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant. NCT01808456 | Inova Health Care Services | Phase 4 |
| Completed | Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subject NCT02344134 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Form NCT01863433 | Seqirus | Phase 4 |
| Completed | A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy V NCT01857297 | Seqirus | Phase 4 |
| Completed | Evaluating Modes of Influenza Transmission NCT01710111 | University of Nottingham | N/A |
| Completed | Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are NCT01753531 | Sekisui Diagnostics, LLC | — |
| Completed | Influenza Vaccine and Pneumococcal Vaccine NCT02582047 | Korea University Guro Hospital | Phase 4 |
| Completed | Jet Injection for Influenza NCT01688921 | PharmaJet, Inc. | Phase 4 |
| Completed | Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines NCT01674205 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | NK Cell Mediated Influenza Immunity During Pregnancy NCT03196245 | Stanford University | — |
| Completed | DNA-based Influenza Vaccine in the Elderly NCT01587131 | University of Manitoba | Phase 1 |
| Completed | A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy V NCT01591837 | Seqirus | Phase 4 |
| Completed | Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge NCT02755948 | Imperial College London | N/A |
| Terminated | Safety Study of FluMist With and Without Ampligen NCT01591473 | AIM ImmunoTech Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients NCT03206346 | Valenta Pharm JSC | Phase 3 |
| Completed | A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection NCT01527110 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza NCT01390025 | Theraclone Sciences, Inc. | Phase 1 |
| Completed | Persistence of Immune Response After Vaccination With Influenza Vaccine NCT01906190 | Centers for Disease Control and Prevention, China | N/A |
| Completed | Safety of Inhaled Zanamivir in Pregnancy NCT01462487 | GlaxoSmithKline | — |
| Completed | A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers NCT01353729 | GlaxoSmithKline | Phase 1 |
| Completed | Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults NCT01314911 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza NCT01231620 | GlaxoSmithKline | Phase 3 |
| Completed | Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males NCT01428479 | GlaxoSmithKline | Phase 1 |
| Completed | Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults NCT01369862 | AVIR Green Hills Biotechnology AG | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsu NCT01258530 | GlaxoSmithKline | Phase 1 |
| Completed | Field Trial of Maternal Influenza Immunization in Asia NCT01034254 | Children's Hospital Medical Center, Cincinnati | Phase 3 |
| Completed | Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections NCT03189537 | Valenta Pharm JSC | Phase 3 |
| Terminated | Clinical Validation of the Point-of-Care MSD Influenza Test NCT00863343 | Meso Scale Diagnostics, LLC. | — |
| Completed | Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections i NCT03154515 | Valenta Pharm JSC | Phase 4 |
| Completed | Dose Finding Study of Single Dose GHB11L1 in Healthy Adults NCT01078701 | AVIR Green Hills Biotechnology AG | Phase 2 |
| Completed | Oseltamivir Infant Influenza Safety Study NCT01286142 | Charite University, Berlin, Germany | — |
| Completed | Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital NCT01014988 | GlaxoSmithKline | Phase 2 |
| Completed | Relenza® Sentinel Site Monitoring Program in Japan NCT01199744 | GlaxoSmithKline | — |
| Completed | VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Foll NCT00995982 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals NCT01381029 | George Washington University | — |
| Completed | Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents NCT01407978 | Fluart Innovative Vaccine Ltd, Hungary | N/A |
| Completed | Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Year NCT00929331 | GlaxoSmithKline | Phase 3 |
| Completed | Prophylactic Efficacy of Relenza Against Influenza A and B NCT01156701 | GlaxoSmithKline | — |
| Completed | VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule o NCT00858611 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Face Masks for Preventing Influenza Transmission NCT00774774 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | A Multinational Phase III Study of CS-8958 (MARVEL) NCT00803595 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Completed | Vaccine for Prevention of Bird Flu NCT00776711 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. NCT00545532 | Hoffmann-La Roche | Phase 3 |
| Completed | Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to NCT00644059 | Novartis | Phase 3 |
| Completed | Revaccination With Influenza Vaccine GSK1247446A NCT00545025 | GlaxoSmithKline | Phase 2 |
| Completed | A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines NCT00558649 | NanoPass Technologies Ltd | N/A |
| Completed | Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis) NCT01390792 | GlaxoSmithKline | — |
| Withdrawn | Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infecti NCT02950688 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |